Citations

Clear

2429 citation(s) found for "Shah, SS".

Cardiovascular degeneration in Erdheim-Chester disease: prevalence, burden, and outcomes
Tawfiq, R., Spears, Grant M. , Young, Jason R., Mahowald, Madeline , Tobin, W. Oliver , Patgunarajah, Ubenthira, Ruan, Gordon , Yi, Dongni , Zanwar, Saurabh , Gruber, Lucinda , Ravindran, Aishwarya , Sartori‐Valinotti, Julio C. , Vassallo, Robert , Ryu, Jay H. , Davidge‐Pitts, Caroline , Dasari, Surendra , Abeykoon, Jithma P. , Tawfiq, Reema K , Mahowald, Madeline K , Ruan, Gordon J , Acosta-Medina, Aldo A , Ravindran, Aishwarya , Shah, Mithun V , Bennani, N Nora , Moustafa, Muhamad Alhaj , Hilal, Talal , Sartori-Valinotti, J C , Vassallo, Robert , Ryu, Jay H , Witzig, T.E. , Goyal, Guarav , Abeykoon, Jithma P , Tobin, W Oliver , Rech, Karen L. , Koster, Matthew J. , Acosta‐Medina, Aldo A. , Shah, Meera , Bennani, N. Nora , Moustafa, Muhamad Alhaj , Hilal, Talal , Witzig, Thomas E. , Go, Ronald S. , Goyal, Gaurav

Mayo Clinic

Blood Advances | August 28, 2025 | Volume: 9 | Issue: 23 | Pages: 5988-6000

10.1182/bloodadvances.2025016608 | PMID 40875593 Get It

Abstract Erdheim-Chester disease (ECD) is a rare systemic histiocytic neoplasm, with cardiac morbidities, including cardiovascular (CV) risk factors and cardiac conditions, playing a significant yet poorly understood role in the disease burden. This study evaluated the prevalence, characteristics, and prognosis of ECD in patients with (ECD-C) and without cardiac involvement (ECD-noC) and compared the burden of cardiac morbidities with matched controls. Patients diagnosed with ECD between 1990 and 2021 at a tertiary center were included, with cardiac involvement centrally assessed using radiographic studies. Cardiac morbidities were compared with a control group without ECD, matched for age, sex, body mass index, and smoking history. Among 104 patients with ECD, 39 (37%) had cardiac involvement. Patients with ECD-C had higher rates of hypertension (67% vs 46%), hyperlipidemia (67% vs 40%), heart failure (36% vs 8%), and pericardial effusion (28% vs 2%) than those with ECD-noC. Compared with the matched non-ECD cohort, patients with ECD had higher prevalence of coronary artery disease (20% vs 7%), heart failure (18% vs 4%), and antihypertensive drug use (55% vs 40%). Notably, patients with ECD-C had inferior progression-free survival (PFS) from frontline therapy compared with patients with ECD-noC (5-year PFS, 28.3% vs 70.5%). These findings highlight the burden of CV risk factors and cardiac conditions in ECD, even without a clinical diagnosis of ECD-C. Importantly, this cardiac morbidity burden is substantial for patients with ECD-C compared with ECD-noC. Our findings highlight the need for comprehensive cardiac risk assessment and management strategies to improve patient outcomes.
Beyond platelet counts: assessing safety of postsplenectomy TPO-RA use in ITP
Alyamany, Ruah , Houghton, Damon E. , Sridharan, Meera , Pruthi, Rajiv K. , Shah, Surbhi , Wolanskyj-Spinner, Alexandra P , Houghton, Damon E , Sridharan, Meera , Godby, Richard , Wolanskyj, Alexandra P. , Go, Ronald S.

Mayo Clinic

Blood Advances | August 28, 2025 | Volume: 9 | Issue: 22 | Pages: 5902-5912

10.1182/bloodadvances.2025017902 | PMID 40875595 Get It

Abstract Immune thrombocytopenia (ITP) carries an increased risk of thrombosis, which may be further amplified by splenectomy and thrombopoietin receptor agonists (TPO-RAs). Although each intervention has been individually studied for its thrombotic risk, data are lacking on the safety of postsplenectomy TPO-RA use. We conducted a retrospective cohort study of adult patients with ITP who underwent splenectomy between 2011 and 2024. Patients were stratified on the basis of postsplenectomy TPO-RA use. The primary outcome was incidence of thrombosis. Secondary outcomes included bleeding, mortality, and hematologic response. Time-to-event analyses and multivariate Cox regression were performed. Among 88 patients, 37 (42%) patients received TPO-RAs after splenectomy. Thrombosis occurred in 17 patients in the TPO-RA group vs 14 patients in the non–TPO-RA group (P = .07). The 10-year cumulative incidence of thrombosis was numerically higher in the TPO-RA group (57% vs 36%), with clustering of events within the 3 months of postsplenectomy TPO-RA initiation. Venous events predominated; arterial events were rare. No significant differences were observed in bleeding or mortality rates between groups. Platelet counts alone did not independently affect bleeding or thrombosis. TPO-RA use after splenectomy was not significantly associated with increased thrombosis risk. However, early initiation may coincide with a high-risk period, and the sustained numerical difference in cumulative incidence throughout follow-up highlights potential clinical relevance. These findings support the need for individualized thromboprophylaxis and prospective evaluation of TPO-RA safety in this setting.
From Error to Expression: How Gene Therapy Is Set to Transform Hemophilia B Management
Padrnos, Leslie , Shah, Surbhi

Mayo Clinic

The Hematologist | August 28, 2025 | Volume: 22 | Issue: 5 | Pages: No page available

10.1182/hem.v22.5.202556 Get It

Spray Cryotherapy Esophageal Consortium Consensus Recommendations for Liquid Nitrogen Spray Cryotherapy in Barrett's Esophagus and Esophageal Cancer Using a Modified Delphi Process
Shah, Tilak , Ansari, Zaid , Ahmad, Akram I. , Coyle, Walter , Greenwald, Bruce B., Kachaamy, Toufic , Kothari, Shivangi , Sharma, Neil , Smallfield, George , Thakkar, Shyam , Tsai, Franklin , Zhang, Han , Friedland, Shai , Mok, Shaffer , Sedarat, Alireza, Smith, Michael S. , Vashi, Pankaj G., Fukami, Norio , Mok, Shaffer , Smith, Michael , Willingham, Field F , Turshudzhyan, Alla , Kaul, Vivek , Greenwald, Bruce B., Fukami, Norio , Vargo, John Joseph , Willingham, Field F.

Mayo Clinic

American Journal of Gastroenterology | August 26, 2025 | Volume: 121 | Issue: 7 | Pages: 1592-1599

10.14309/ajg.0000000000003752 | PMID 40856659 Get It

INTRODUCTION: The study aimed to develop consensus recommendations for the safe and appropriate use of liquid nitrogen spray cryotherapy in Barrett's esophagus and esophageal cancer. METHODS: Statements were initially formulated and grouped into categories of indications, training, preprocedure, intraprocedure, and postprocedure recommendations, frequency/timing of repeat procedures, and contraindications. Two investigators assessed the strength of the evidence for each statement using Grading of Recommendations Assessment, Development, and Evaluation methodology. Nineteen experts were invited to participate in a modified Delphi process. For statements that received >80% agreement, minor iterative edits were performed until there was unanimous consensus. If a threshold of 80% agreement was not reached, the statement was modified based on feedback and included in the next Delphi round. Statements were rejected if no consensus was reached after 3 rounds. RESULTS: After 3 Delphi rounds, 41 of 42 statements were accepted either in their original version (n = 11) or after modification based on expert input (n = 30). DISCUSSION: Through a modified Delphi process, we developed expert and evidence-based consensus recommendations to guide safe and appropriate use of liquid nitrogen spray cryotherapy in Barrett's esophagus and esophageal cancer.
Quadriparesis after CD19 × CD22 bicistronic chimeric antigen receptor T cells for B‐cell acute lymphoblastic leukaemia
Rankin, Alexander W. , Duncan, Brynn B. , Yates, Bonnie , Nath, Avindra , Biassou, Nadia , Suffredini, Anthony F. , Danner, Robert L. , Natanson, Charles , Ahluwalia, Amarpreet K., Foley, Toni, Shalabi, Haneen , Duncan, Brynn B , Murthy, Hemant S , Shah, Nirali N , Rankin, Alexander W , Silbert, Sara K. , Ahluwalia, Amarpreet K., Little, Lauren, Murthy, Hemant S. , Nyquist, Paul

Mayo Clinic

British Journal of Haematology | August 26, 2025 | Volume: 207 | Issue: 4 | Pages: 1673-1678

10.1111/bjh.70073 | PMID 41070663 Get It

Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Lurz, Philipp , Hahn, Rebecca T. , Kodali, Susheel , Makkar, Raj , Sharma, Rahul , Davidson, Charles J. , O’Neill, Brian , Yadav, Pradeep , Zahr, Firas , Chadderdon, Scott , Eleid, Mackram F. , Smith, Robert L, Garcia, Santiago , Kister, Tobias , Kipperman, Robert, Lim, Scott, Hermiller, James, Mishell, Jacob M. , Rassi, Andrew N., Szeto, Wilson Y. , Babaliaros, Vasilis , Barker, Colin M. , Summers, Matthew , Chetcuti, Stanley, Ailawadi, Gorav , Russo, Mark, Rinaldi, Michael, Chehab, Bassem , Nickenig, Georg, Stinis, Curtiss, Inglessis‐Azuaje, Ignacio , Dhoble, Abhijeet , Petrossian, George , Shah, Pinak, Staniloae, Cezar , Nores, Marcos, Singh, Gagan D. , Baldus, Stephan , Rudolph, Volker , Barb, Ilie, Klodell, C.T., Gray, William A. , Strote, Justin A, Sannino, Anna , Grayburn, Paul , Mack, Michael J. , Leon, Martin B. , Thourani, Vinod H. , Lim, D. Scott , Szerlip, Molly , Kister, Tobias , Lim, D Scott , Saxon, John , Kapadia, Samir , Mishell, Jacob M , Herrmann, Howard C , Hausleiter, Jörg , Babaliaros, Vasilis , Barker, Colin M , Lindman, Brian R , Latib, Azeem , von Bardeleben, Ralph Stephan , Summers, Matthew , Ailawadi, Gorav , Rinaldi, Michael , Chehab, Bassem M , Nickenig, Georg , Inglessis-Azuaje, Ignacio , Dhoble, Abhijeet , Chhatriwalla, Adnan K , Petrossian, George , Shah, Pinak , Staniloae, Cezar , Williams, Mathew , McCabe, James M , Singh, Gagan , Baldus, Stephan , Rudolph, Volker , Klodell, Charles , Gray, William , Strote, Justin , Sannino, Anna , Grayburn, Paul , Mack, Michael J , Thourani, Vinod H , Davidson, Charles J. , Hahn, Rebecca T , Lurz, Philipp , Smith, Robert L, Whisenant, Brian K. , Kapadia, Samir , Hausleiter, Jörg , Lindman, Brian R. , Latib, Azeem , Muhammad, Kamran I. , Williams, Mathew

Mayo Clinic

European Heart Journal | August 21, 2025 | Volume: 47 | Issue: 17 | Pages: 2059-2073

10.1093/eurheartj/ehaf676 | PMID 40878717 Get It

Abstract Background and Aims The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.
Diagnostic Utility of PRAME in Rare Melanoma Mimics: A Comparative Analysis Including GNET, MMNST, Epithelioid MPNST, and MITF‐Rearranged Melanocytic Tumors
Shah, Ahmed , Molligan, Jeremy , Dehner, Carina , Torres‐Mora, Jorge , Shah, Ahmed , Molligan, Jeremy F , Dehner, Carina A , Shah, Ahmed

Mayo Clinic

Journal of Cutaneous Pathology | August 18, 2025 | Volume: 52 | Issue: 11 | Pages: 710-719

10.1111/cup.14849 | PMID 40819908 Get It

ABSTRACTBackgroundDifferentiating metastatic melanoma from histologic mimics such as malignant gastrointestinal neuroectodermal tumor (GNET), malignant melanotic nerve sheath tumor (MMNST), and epithelioid malignant peripheral nerve sheath tumor (EMPNST) poses significant diagnostic challenges due to overlapping morphology and immunophenotypes. PRAME is a novel immunohistochemical marker increasingly used to distinguish melanoma from its mimics, but remains underexplored in these rare tumor types.MethodsPRAME immunohistochemistry was performed on four GNETs, seven MMNSTs, 10 EMPNSTs, 16 metastatic melanomas (including eight undifferentiated melanomas), and two MITF‐rearranged melanocytic tumors. PRAME expression was scored from 0 to 4+ based on the percentage of tumor nuclei showing moderate to strong staining.ResultsAll GNETs, MMNSTs, and MITF‐rearranged tumors were PRAME‐negative. EMPNSTs showed variable expression: six were negative (0–1), one equivocal (2+), and three positive (3–4+). Fifteen of 16 melanomas were PRAME‐positive. PRAME scores differed significantly among tumor types (p = 1.99 × 10−5). PRAME demonstrated high sensitivity and specificity for distinguishing metastatic melanoma from primary mimickers including GNET and MMNST, but low specificity in EMPNST (71.4%).ConclusionsPRAME reliably distinguishes metastatic melanoma from GNET and MMNST, supporting its use in this differential. However, its reduced specificity in EMPNST limits its standalone diagnostic value in this context, emphasizing the need for a multimodal approach.
Anatomy of the Prostate and Periprostatic Region: A Contemporary Review, From the AJR Special Series on Critical Anatomy
Cheney, Scott M, Yano, Motoyo , Gupta, Amar C, Costa, Daniel Nobrega da , Gupta, Amar C. , Shah, Rajal B.

Mayo Clinic

American Journal of Roentgenology | August 13, 2025 | Volume: 226 | Issue: 5 | Pages: No page available

10.2214/ajr.25.33454 | PMID 40801496 Get It